NASDAQ:LABP - Nasdaq - US5150692011 - Common Stock - Currency: USD
/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the...
Mentions: ABBV
LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the first quarter of 2024.
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.
Mentions: ABBV
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Investors are wondering if the stock market is closed on Good Friday 2024 as they prepare for the upcoming Easter weekend.
LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Landos Biopharma (NASDAQ:LABP) just reported results for the fourth quarter of ...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million.
/PRNewswire/ -- Ademi LLP is investigating Landos (NASDAQ: LABP) for possible breaches of fiduciary duty and other violations of law in its transaction with...
/PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which...
Mentions: ABBV
- Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)...
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned...
Six Presentations Highlight Landos’ Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative...
NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement...
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund...
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral...
Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models...
Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash...